Comparison of the diagnostic performance of three natriuretic peptides in hemodialysis patients: Which is the appropriate biomarker?

Kidney and Blood Pressure Research

Volumn 36, Issue 1, 2012, Pages 172-181

  Artunc, Ferruh ^a,d   Mueller, Christian ^b   Breidthardt, Tobias ^b   Twerenbold, Raphael ^b   Rettig, Ingo ^a   Usta, Engin ^a   Häring, Hans Ulrich ^a   Friedrich, Björn ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Dialysis Center   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Hemodialysis; Mortality; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; MIDREGIONAL PRO ATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR FUNCTION; CONCENTRATION (PARAMETERS); CROSS-SECTIONAL STUDY; DIAGNOSTIC PROCEDURE; DIURESIS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTOLIC DYSFUNCTION; WEIGHT GAIN;

AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84867897036     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000343406     Document Type: Article

References (26)

1. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D: N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007;71:548-554.
2. Sun L, Sun Y, Zhao X, Xu C, Chen D, Li L, Ma Y, Rong S, Mei C: Predictive role of BNP and NT-proBNP in hemodialysis patients. Nephron Clin Pract 2008;110:c178-c184.
3. Goto T, Takase H, Toriyama T, Sugiura T, Kurita Y, Tsuru N, Masuda H, Hayashi K, Ueda R, Dohi Y: Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002;92:610-615.
4. Wang AY, Lai KN: Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008;19:1643-1652.
5. Spinar J, Ludka O, Dusek L, Vitovcova L, Sobotova D, Spinarova L, Tomandl J, Vitovec J: Neurohumoral activity, heart failure and prognosis in patients with end-stage renal disease treated by hemodialysis. Kidney Blood Press Res 2007;30:347-357.
6. de Lemos JA, McGuire DK, Drazner MH: B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-322.
7. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, Fujii M, Yamamoto T, Dohke T, Ohnishi M, Takashima H, Kinoshita M, Horie M: Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006;47:582-586.
8. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
9. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, Pfisterer M, Perruchoud AP: Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-654.
10. Buckley MG, Marcus NJ, Yacoub MH: Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci (Lond) 1999;97:689-695.
11. Numata Y, Dohi K, Furukawa A, Kikuoka S, Asada H, Fukunaga T, Taniguchi Y, Sasakura K, Tsuji T, Inouye K, Yoshimura M, Itoh H, Mukoyama M, Yasue H, Nakao K: Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma. Clin Chem 1998;44:1008-1013.
12. Missbichler A, Hawa G, Schmal N, Woloszczuk W: Sandwich ELISA for proANP 1-98 facilitates investigation of left ventricular dysfunction. Eur J Med Res 2001;6:105-111.
13. Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of proatrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-236.
14. Gouya G, Sturm G, Lamina C, Zitt E, Freistatter O, Struck J, Wolzt M, Knoll F, Lins F, Lhotta K, Neyer U, Kronenberg F: The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort. PLoS One 2011;6:e17803.
15. Dieplinger B, Mueller T, Kollerits B, Struck J, Ritz E, von EA, Haltmayer M, Kronenberg F: Pro-A-type natriuretic peptide and pro-adrenomedullin predict progression of chronic kidney disease: the MMKD Study. Kidney Int 2009;75:408-414.
16. Kamano C, Osawa H, Hashimoto K, Nishimura S, Saito SK, Kashiwagi T, Iino Y, Katayama Y: N-Terminal Pro-Brain Natriuretic Peptide as a Predictor of Heart Failure with Preserved Ejection Fraction in Hemodialysis Patients without Fluid Overload. Blood Purif 2011;33:37-43.
17. McCullough PA, Sandberg KR: B-type natriuretic peptide and renal disease. Heart Fail Rev 2003;8:355-358.
18. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D: Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 2008;23:1370-1377.
19. Nakatani T, Naganuma T, Masuda C, Sugimura T, Uchida J, Takemoto Y, Sugimura K: The prognostic role of atrial natriuretic peptides in hemodialysis patients. Blood Purif 2003;21:395-400.
20. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, Mockel M, Hogan C, Wu AH, Richards M, Clopton P, Filippatos GS, Di SS, Anand I, Ng L, Daniels LB, Neath SX, Christenson R, Potocki M, McCord J, Terracciano G, Kremastinos D, Hartmann O, von HS, Bergmann A, Morgenthaler NG, Anker SD: Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55:2062-2076.
21. Januzzi JL, Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-954.
22. Wegner M, Ganten D, Stasch JP: Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats. Hypertens Res 1996;19:229-238.
23. Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui K: Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 1999;370:307-312.
24. Mueller C, Laule-Kilian K, Scholer A, Nusbaumer C, Zeller T, Staub D, Perruchoud AP: B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison. Kidney Int 2005;67:278-284.
25. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, Herrmann HC, Steg PG, Westheim A, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS: B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-579.
26. van der Wal WM, Noordzij M, Dekker FW, Boeschoten EW, Krediet RT, Korevaar JC, Geskus RB: Full loss of residual renal function causes higher mortality in dialysis patients; findings from a marginal structural model. Nephrol Dial Transplant 2011;26:2978-2983.